Skip to content

Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.

Eur Arch Psychiatry Clin Neurosci August 29, 2026 DOI: 10.1007/s00406-026-02361-4 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort Peer reviewed
Population Patients with treatment-resistant depression
Interventions Esketamine Depression-specific metacognitive training
Duration 6-month follow-up
Topics Depression Esketamine
Key findings Depressive symptoms and rumination improved over six months across all treatment groups, with the combination of esketamine and metacognitive training showing the largest reductions, suggesting an additive benefit of the combined approach.

Abstract

Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.